# D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC

> **NCT07016126** · PHASE3 · RECRUITING · sponsor: **Guangdong Provincial People's Hospital** · enrollment: 70 (estimated)

## Conditions studied

- NSCLC (Non-small Cell Lung Cancer)

## Interventions

- **COMBINATION_PRODUCT:** D-BACE in combination with chemotherapy and karelizumab

## Key facts

- **NCT ID:** NCT07016126
- **Lead sponsor:** Guangdong Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-22
- **Primary completion:** 2027-12-22
- **Final completion:** 2027-12-22
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07016126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07016126, "D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07016126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*